RECOMBINANT IGF-1 USE IN SIBLINGS WITH LARON SYNDROME

FIRST 2 CASES TREATED IN MALAYSIA

Authors

  • Nurshadia Samingan University Malaya Medical Centre, Kuala Lumpur, Malaysia
  • Meenal Mavinkurve International Medical University, Seremban, Malaysia
  • Mazidah Noordin University Teknologi Mara (UiTM), Shah Alam, Malaysia
  • Annie Leong Hospital Putrajaya, Malaysia
  • Azriyanti Anuar Zaini Department of Paediatrics
  • Siti Zarina Yaakop University Malaya Medical Centre, Kuala Lumpur, Malaysia
  • Muhammad Yazid Jalaludin Department of Paediatrics

DOI:

https://doi.org/10.15605/jafes.036.S95

Keywords:

laron syndrome, recombinant

Abstract

INTRODUCTION
Laron Syndrome (LS) is a rare cause of extreme poor growth in children due to the mutation of GHR gene. It is characterised by postnatal growth failure, with midface hypoplasia and obesity. Growth hormone level is normal or elevated with low IGF 1 value. Severe short stature is the major disability in untreated adults. Recombinant IGF 1 hormone (rIGF1) is the only approved treatment since 2007.

RESULTS
We present the case of 2 siblings, whom parents are consanguineous. H presented at 11.5 years old with short stature and being obese; height 121 cm (-3.39 SDS), weight 41.8kg (+0.8 SDS) and BMI 28.55kg/m2 (+2.91 SDS). His birth weight and length were 3kg and 50 cm (-0.5 SDS and +0.3 SDS). Genetic test confirmed homozygous mutation at the GHR gene and presence of heterozygous gene mutation in both parents. The youngest sibling, K was born with birth weight of 3.2kg (+0.98 SDS). At 2.9 years old, K was severely stunted. His height and weight were 64.6cm (-7.67 SDS) and 6.18kg (-8.95 SDS). Both patients scored 4 out of 5 on Savage Scoring System. Recombinant IGF1 (mecasermin) was initiated at the age of 12.7 years and 4.1 years, respectively. At 10 months post rGH1, all growth parameters improved remarkably. Pre- and posttreatment height velocity and serum IGF 1 for H and K were (4.2cm vs 14.8cm)/year and (4cm vs 17.6cm)/year, (47 vs 329) µmol/L and (<15 vs 205) µmol/L, respectively. Hypoglycaemia, a common side effect of treatment was not reported. H’s percentage body fat and muscle mass improved from 54.1% to 52% and 10.8kg to 12.4kg. One year treatment for both siblings’ costs RM751,500 (USD 182,624.57)

CONCLUSION
LS is rare, yet a treatable cause for severe short stature. Albeit the exorbitant cost, treatment offers positive outlook.

Downloads

Download data is not yet available.

Author Biographies

Nurshadia Samingan, University Malaya Medical Centre, Kuala Lumpur, Malaysia

Department of Paediatrics

University Malaya, Kuala Lumpur, Malaysia

Meenal Mavinkurve, International Medical University, Seremban, Malaysia

Department of Paediatrics

Mazidah Noordin, University Teknologi Mara (UiTM), Shah Alam, Malaysia

Department of Paediatrics

Annie Leong, Hospital Putrajaya, Malaysia

Department of Paediatrics

Azriyanti Anuar Zaini, Department of Paediatrics

University Malaya Medical Centre, Kuala Lumpur, Malaysia

University Malaya, Kuala Lumpur, Malaysia

Siti Zarina Yaakop, University Malaya Medical Centre, Kuala Lumpur, Malaysia

Department of Paediatrics

Muhammad Yazid Jalaludin, Department of Paediatrics

University Malaya Medical Centre, Kuala Lumpur, Malaysia

University Malaya, Kuala Lumpur, Malaysia

References

*

Published

2021-07-28

How to Cite

Samingan, N. ., Mavinkurve, M. ., Noordin, M. ., Leong, A. ., Zaini, A. A., Yaakop, S. Z. ., & Jalaludin, M. Y. . (2021). RECOMBINANT IGF-1 USE IN SIBLINGS WITH LARON SYNDROME: FIRST 2 CASES TREATED IN MALAYSIA. Journal of the ASEAN Federation of Endocrine Societies, 36, 63–64. https://doi.org/10.15605/jafes.036.S95

Issue

Section

Abstracts for Poster Presentation | Paediatric

Most read articles by the same author(s)

1 2 3 4 > >>